Skip to main content
MyDeficiencies

Temazepam

benzodiazepine derivative, hypnotic

Also sold as Restoril.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Temazepam has no established classical nutrient-depletion mechanism. The FDA label shows it is cleared almost entirely by direct glucuronide conjugation, not oxidative CYP450 metabolism: minimal (8%) first-pass metabolism, no active metabolites, 80 to 90% of the dose recovered in urine as O-glucuronide conjugates, no documented CYP450 induction or inhibition, and no food, mineral, or antacid interaction described anywhere in the label. This places temazepam in the same low-plausibility metabolic category as lorazepam, a fellow directly-glucuronidated benzodiazepine already reviewed in this series, rather than in the CYP3A4-oxidized category of diazepam or alprazolam, whose hepatic-induction and interaction profiles create more classical depletion machinery to examine in the first place.

benzodiazepine derivative, hypnotic · ATC N05CD07 · also sold as Restoril · reviewed 2026-09-29. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Temazepam in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Melatonin

Not graded — disclosed evidence gap

See study details

Temazepam appears in the literature only as a comparator to exogenous melatonin in insomnia and performance trials, never as a study of temazepam suppressing the body's own melatonin production. This repair pass confirmed that conclusion by directly reading both key comparator abstracts, rather than inferring it from blocked pages, and still found no drug-specific depletion evidence and no clearly sourced consumer claim.

Full detail, limits and 2 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED · EVIDENCE GAP

Limits on what this shows

  • Why no grade: Dual condition met, and now more firmly established for temazepam itself than in the original review: the two most relevant abstracts were this time successfully read in full rather than inferred from titles, and neither is a depletion study; no circulating claim was found to rebut as white.

Channels tried

Original review: PubMed ("temazepam AND melatonin", 10 results), direct PubMed abstract fetch for the two most relevant comparator studies, Europe PMC and Semantic Scholar follow-up, and the RxList and Drugs.com consumer pages. This repair pass re-attempted direct PubMed abstract access for both key PMIDs (again blocked by a bot-verification page), then used OpenAlex per-record lookup as a fallback channel, and separately attempted two class-level searches, "benzodiazepine AND melatonin secretion" and "diazepam AND pineal AND melatonin," to check for a Tier C extrapolation.

Outcome

The OpenAlex fallback succeeded where direct PubMed access had failed, returning full abstracts for both key studies. Gilbert et al. 1999 (PMID 9882760) compared exogenous melatonin (5 mg) against temazepam (20 mg) on sleep latency and body temperature in 20 young adults; Rogers et al. 2003 (PMID 12941059) compared exogenous melatonin (5 mg) against temazepam (10 mg) on neurobehavioral performance in 16 young adults. Both are confirmed, on full-text abstract review, to be head-to-head comparator trials of exogenous melatonin versus temazepam as alternative hypnotics; neither measures temazepam's effect on the body's own melatonin secretion. RxList and Drugs.com again list no melatonin interaction or depletion claim for temazepam. Both class-level searches (benzodiazepine/diazepam and endogenous melatonin) were blocked this session by the same gateway-level policy denial described under Copper above, before either could return a result.

Genuine gap vs. tooling-limited

Genuine gap for temazepam itself, now confirmed by successfully reading both key primary sources. Tooling-limited only for the supplementary class-level (diazepam/benzodiazepine) extrapolation search attempted in this pass, which could not be completed; a future revision should retry that specific angle before concluding no class-level Tier C evidence exists at all.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

Evidence in: TIER B/C, CLASS EXTRAPOLATION

The 1,4-benzodiazepine class can bind a mitochondrial outer-membrane site, the translocator protein, and a different class member, diazepam, has measurable mitochondrial effects in animal and cell models, but no study has tested temazepam itself, and the diazepam data trend protective, not damaging.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · TIER B/C, CLASS EXTRAPOLATION

Limits on what this shows

  • Key negative/null findings: PubMed search "temazepam AND mitochondria" returned zero results. "Benzodiazepine translocator protein mitochondria temazepam" also returned zero results.
  • At-risk subgroups: None identified; no human data exists to define one.

Regulatory status

Not addressed in the FDA label. No mitochondrial toxicity signal is listed for temazepam.

Population evidence

None for temazepam. For diazepam: Sarnowska et al. 2009 (Neurochem Int, PMID 19428822) found diazepam's neuroprotection in excitotoxic and oxidative-stress models involved a mitochondrial mechanism in addition to GABA-A receptor binding and hypothermia, in rat neuron cultures. Ghasempouri et al. 2023 (Toxicol Rep, PMID 37955036) found diazepam protected mouse brain mitochondria against ethanol-induced disruption. Both studied diazepam, not temazepam.

Mechanism

Named: the translocator protein (TSPO), a mitochondrial outer-membrane cholesterol-transport site the 1,4-benzodiazepine class can bind (Barresi et al. 2021, Eur J Med Chem, PMID 33081988). Temazepam's clinical-dose affinity for TSPO relative to its central GABA-A alpha-subunit target was not addressed in any source reviewed.

Counter-evidence held on record

The only drug-specific mitochondrial data available anywhere in this class (diazepam) point toward mitochondrial protection, not injury, in acute excitotoxic, oxidative-stress, and ethanol-challenge models. This runs counter to a narrative sometimes advanced in benzodiazepine-withdrawal patient communities that the drug class causes cumulative mitochondrial damage; this review located no temazepam-specific data that either supports or refutes that narrative directly, and no chronic-use or withdrawal-phase mitochondrial data for any benzodiazepine at Tier A or Tier B. Framing caution: do not present this entry as evidence that temazepam protects mitochondria. The supporting data are for a different drug, come from acute-exposure animal and cell models, and have not been tested in chronic human use or in withdrawal.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

Evidence in: TIER B/C, CLASS EXTRAPOLATION

Diazepam measurably shifts brain pro-oxidant/antioxidant balance in animal models, improving it during treatment and disturbing it around withdrawal. Temazepam itself has no published oxidative-stress data at all.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · TIER B/C, CLASS EXTRAPOLATION

Limits on what this shows

  • Key negative/null findings: Zero results for temazepam paired with oxidative stress. A broad "benzodiazepine AND oxidative stress" search returned no hits specific to any hypnotic or anxiolytic benzodiazepine, only unrelated antiepileptic and antipsychotic drug studies.
  • At-risk subgroups: Not defined for temazepam. The withdrawal-phase shift seen with diazepam may be most relevant to abrupt discontinuation after prolonged use, a recognized clinical risk for any benzodiazepine, but this was not measured for temazepam.

Regulatory status

Not addressed in the FDA label.

Population evidence

None for temazepam (zero PubMed results for "temazepam AND oxidative stress"). For diazepam: Musavi and Kakkar 2003 (Mol Cell Biochem, PMID 12708744) measured pro-/antioxidative markers in rat brain during diazepam treatment and again after its withdrawal, and found the two phases moved in different directions. Mendez-Cuesta et al. 2011 (Basic Clin Pharmacol Toxicol, PMID 21645264) found diazepam blocked striatal lipid peroxidation in a rat acute-stress model.

Mechanism

Proposed via GABA-A-mediated reduction of excitotoxic calcium influx, and possibly via TSPO; no vitamin or mineral cofactor is implicated in any source reviewed.

Counter-evidence held on record

The two diazepam studies point in opposite directions depending on treatment phase, which itself argues against a simple "benzodiazepines steadily deplete antioxidant capacity" narrative; where a class effect exists at all, it appears phase-dependent rather than a steady depletion. Framing caution: this entry rests entirely on a different drug, diazepam, studied as an anxiolytic. It does not establish that temazepam, used nightly at hypnotic doses specifically for insomnia, behaves the same way.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No mechanism, no drug-specific data, and no circulating consumer claim links temazepam to copper status. A dedicated repair pass re-ran this search with an additional phrasing and several alternate channels, and the conclusion is unchanged.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED · EVIDENCE GAP

Limits on what this shows

  • Why no grade: Dual condition met on the evidence actually retrievable: the one channel that returned results (PubMed, "temazepam AND copper") gave a clean zero on both the original and repeat test, and no circulating claim was found.

Channels tried

Original review: PubMed search-listing pages ("temazepam AND copper"), the FDA/DailyMed label, and the Drugs.com and RxList consumer interaction pages. This repair pass added: a second PubMed phrasing ("temazepam AND ceruloplasmin"), and attempted OpenAlex works-search, Europe PMC REST search, Crossref API, Semantic Scholar API, and a DuckDuckGo web search as further fallback channels.

Outcome

"temazepam AND copper" again returned zero PubMed results on retest, consistent with the original review. No mention in the label or either consumer reference. The "ceruloplasmin" phrasing and all four alternate-API channels (OpenAlex, Europe PMC, Crossref, Semantic Scholar) were blocked this session by a persistent gateway-level policy denial, confirmed via the proxy's own connection-level diagnostic as repeated 403 responses to the CONNECT request itself, not ordinary per-request rate limiting; the same block affected pubmed.ncbi.nlm.nih.gov, eutils.ncbi.nlm.nih.gov, dailymed.nlm.nih.gov, and api.fda.gov for extended periods during this session. The DuckDuckGo fallback was separately refused by that site's own robots.txt rules.

Genuine gap vs. tooling-limited

Genuine gap for the core PubMed channel, reconfirmed on retest. Several supplementary channels could not be genuinely completed this pass due to the gateway-level block described above, so this should be read as a well-supported but not exhaustively multi-channel-confirmed gap, worth another check once broader API access is available.

Iron

Not graded — disclosed evidence gap

See study details

No mechanism or drug-specific evidence links temazepam to iron status. The only tangential hit remains a case report listing temazepam as one of several treatment options for restless legs syndrome, a condition independently associated with iron deficiency, which is not evidence of temazepam depleting iron; a fresh ferritin-specific search in this repair pass also returned zero results.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED · EVIDENCE GAP

Limits on what this shows

  • Why no grade: Dual condition met. The restless-legs hit remains confounding by indication, not a depletion claim, and the fresh ferritin-specific PubMed search adds a second, independently phrased clean negative.

Channels tried

Original review: PubMed ("temazepam AND iron"), the DailyMed label, Drugs.com, and RxList. This repair pass added a second, independently phrased PubMed search ("temazepam AND ferritin") and attempted OpenAlex, Europe PMC, Crossref, and Semantic Scholar follow-up channels.

Outcome

"temazepam AND ferritin" returned zero results, a clean negative that reinforces the original "temazepam AND iron" finding. The two original tangential hits are unchanged: Umbreit et al. 2021 (PMID 34032164) mentions temazepam only as one option among several for restless legs syndrome, a disorder with an iron-deficiency association that predates and is independent of any hypnotic prescribed for its insomnia symptom; Bekele et al. 2011 (PMID 21914556) is an unrelated water-quality study that matched on keyword overlap only. The OpenAlex, Europe PMC, Crossref, and Semantic Scholar follow-up channels were blocked this session by the same gateway-level policy denial described under Copper above.

Genuine gap vs. tooling-limited

Genuine gap, now reconfirmed with a second, differently phrased PubMed search in this pass; the blocked supplementary API channels do not change this conclusion, since the primary PubMed channel returned clean, interpretable results both times it was tried.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

Evidence in: TIER B/C, CLASS EXTRAPOLATION

The only benzodiazepine-and-microbiome study located used flunitrazepam, not temazepam, in zebrafish exposed at environmental contamination levels, not therapeutic human dosing.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · TIER B/C, CLASS EXTRAPOLATION

Limits on what this shows

  • Key negative/null findings: Zero temazepam results. The broader "benzodiazepine AND gut microbiota" search surfaced mostly unrelated antipsychotic (olanzapine) microbiome studies, not benzodiazepine-class findings.
  • At-risk subgroups: None defined; not applicable to a fish ecotoxicology model.

Regulatory status

Not addressed in the FDA label.

Population evidence

None for temazepam (zero PubMed results for "temazepam AND microbiome"). Lin et al. 2023 (Sci Total Environ, PMID 37532048) found flunitrazepam produced neurotoxicity in zebrafish that the authors attributed in part to microbiota-gut-brain axis disruption, at waterborne concentrations modeling environmental drug contamination, not clinical dosing.

Mechanism

Proposed gut-microbiota-brain axis signaling; not tied to any classical nutrient and not tested in mammals.

Counter-evidence held on record

No mammalian or clinical-dose data exist for any benzodiazepine and the gut microbiome. The single supporting study used a different drug, a different species, and an environmental rather than therapeutic exposure route. Framing caution: this is the weakest form of class extrapolation retained in this dossier. It is kept, rather than dropped to ungraded, only because it is a real, drug-specific (for flunitrazepam) mechanistic finding rather than pure speculation, and should not be read as evidence that temazepam disrupts the human gut microbiome.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production

Yellow — Low

Evidence in: TIER B/C, CLASS EXTRAPOLATION

A 1998 study found diazepam and a second, unrelated psychotropic drug each produced an uncoupling effect on oxidative phosphorylation in isolated rat liver mitochondria, meaning less ATP synthesized per unit of oxygen consumed. No study has tested temazepam itself, and this finding runs opposite to the protective brain-mitochondria effects reported for diazepam under Mitochondrial burden above.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · TIER B/C, CLASS EXTRAPOLATION

Limits on what this shows

  • Key negative/null findings: The original review's PubMed search "temazepam AND ATP" returned zero results. This repair pass's attempt at a second corroborating source, "diazepam AND ATP AND oxidative phosphorylation," was blocked by persistent gateway-level rate-limiting before a result could be confirmed, so this entry rests on one study only.
  • At-risk subgroups: None identified; no human data exists to define one.

Regulatory status

Not addressed in the FDA label. No ATP or oxidative-phosphorylation effect is listed for temazepam.

Population evidence

None for temazepam. For diazepam (marketed as Relanium in the study) and imipramine (marketed as Melipramine, an unrelated tricyclic antidepressant, included as a second test drug): Burbenskaya et al. 1998 (IUBMB Life, PMID 9678247) found both drugs increased oxygen consumption and produced an uncoupling effect on oxidative phosphorylation in isolated rat liver mitochondria. Cohort confirmed via an OpenAlex per-record lookup after the original review's direct PubMed and Europe PMC attempts were blocked; the source is a different drug (diazepam, not temazepam), a different tissue (liver, not brain/CNS), and a different exposure paradigm (isolated mitochondria, direct in vitro drug exposure) from the diazepam mitochondrial-protection studies cited under Mitochondrial burden above.

Mechanism

Named: uncoupling of the mitochondrial electron transport chain from ATP synthase in isolated rat liver mitochondria, raising oxygen consumption without a matching rise in ATP yield. Not tied to the translocator protein (TSPO) mechanism cited elsewhere in this dossier; the 1998 study does not address TSPO, and no vitamin or mineral cofactor is implicated.

Counter-evidence held on record

This finding runs opposite to the diazepam mitochondrial-protection data cited under Mitochondrial burden above (Sarnowska 2009, Ghasempouri 2023), which used brain/neuronal tissue and excitotoxic or ethanol-challenge stress models rather than baseline isolated liver mitochondria. The two diazepam literatures are not directly comparable, different tissue, different stressor, decades apart, so this dossier records both rather than resolving the apparent tension. No temazepam-specific data exists in either direction. Framing caution: this entry rests on a single, 1998, isolated-liver-mitochondria study of a different drug, diazepam, and is not replicated or corroborated by a second source. It should not be read as evidence that temazepam impairs ATP production, and should not be combined with the Mitochondrial burden entry as if it were confirmatory: the two diazepam findings point in different directions and involve different tissues.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Oxygen delivery/utilization

    Where it comes from: Plausible clinical concern, not consumer marketing: that a sedating, respiratory-depressant hypnotic could impair oxygen saturation or delivery, especially in populations already prone to hypoxemia (high altitude, COPD, congestive heart failure, obstructive sleep apnea). The concern has a real, labeled basis: the FDA label documents additive CNS/respiratory-depressant effects with opioids, alcohol, and other sedatives.

    Why it fails: Five independent Tier A, temazepam-specific studies test this directly at monotherapy hypnotic doses and find no clinically meaningful impairment. A high-altitude RCT found temazepam did not reduce mean oxygen saturation and produced fewer large (>4%) desaturation events than placebo (Dubowitz 1998, BMJ, PMID 9518909). A severe normocapnic COPD RCT found temazepam 10 mg did not affect breathing or gas exchange (Stege 2010, Respir Med, PMID 19910177). A congestive-heart-failure crossover study (n=7) found overnight oxygen saturation essentially unchanged with temazepam, with one partially discordant note: a small, non-significance-tested numeric rise in apnea/hypopnea index (10 to 15.6 events/hour) that this dossier flags rather than omits (Biberdorf 1993, Sleep, PMID 8235237). A second high-altitude RCT found no significant difference in nocturnal oxygen saturation between temazepam and acetazolamide (84.1% vs. 84.4%, p=0.57) (Tanner 2013, High Alt Med Biol, PMID 24028643). A Cochrane systematic review of sedating medications in obstructive sleep apnea, which included a temazepam 15 mg trial among its 14 studies, found no evidence of a deleterious effect on apnea-hypopnea index or oxygen desaturation for the hypnotics studied, unlike the opioid remifentanil, which did show significant desaturation (Mason 2015, Cochrane Database Syst Rev, PMID 26171909). The claim is not merely unproven, it was actively tested across four different at-risk populations at monotherapy hypnotic doses and not supported. This verdict covers temazepam monotherapy only; it does not cancel the FDA label's separate warning about additive respiratory depression in combination with opioids, alcohol, or other CNS depressants, addressed in the Pharmacokinetic basis and Monitoring panel.

How the body handles this medication

Metabolism
Minimal (8%) first-pass effect, no active metabolites formed. Cleared almost entirely by direct O-glucuronide conjugation: 90% as the O-conjugate of temazepam, 7% as the O-conjugate of N-desmethyltemazepam, not by oxidative CYP450 metabolism.FDA label via DailyMed, RESTORIL (SpecGx LLC), setid bc56f7fd-1aaf-48ff-8aa7-d467e59e1015, Clinical Pharmacology
Elimination
80 to 90% of the dose is recovered in urine as conjugates. The label documents no appreciable excretion of unchanged drug and no renal tubular electrolyte-handling effect.Same label, Clinical Pharmacology
Enzyme interactions
No CYP450 induction or inhibition is documented anywhere in the label. Cimetidine, dosed per its own labeling, does not alter temazepam's pharmacokinetic profile.Same label, Drug Interactions
Absorption and protein binding
96% bound to plasma proteins. Measurable plasma levels within 10 to 20 minutes of dosing, peak 1.2 to 1.6 hours after dosing. No chelation, gastric-pH, or mineral/antacid interaction is described.Same label, Clinical Pharmacology
Half-life and class position
Terminal half-life 3.5 to 18.4 hours, mean 8.8 hours. ATC N05CD07, defined daily dose 20 mg oral, classed under hypnotics and sedatives rather than the anxiolytic benzodiazepine subgroup.WHO ATC/DDD Index, atcddd.fhi.no, code N05CD07
Renal/hepatic impairment and pregnancy
Label advises only general caution ("usual precautions") in renal or hepatic impairment, with no accumulation data quantified in the sections reviewed. Neonatal sedation and/or withdrawal is reported with benzodiazepine use late in pregnancy.Same label, Use in Specific Populations
All references used above
  1. RESTORIL (temazepam) capsule, FDA-approved label — SpecGx LLC, via DailyMed, Clinical Pharmacology, Drug Interactions, Use in Specific Populations sections
  2. DailyMed SPL listing for temazepam — Used to locate the Restoril setid among generic listings
  3. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index — ATC N05CD07, DDD 20 mg, oral
  4. Drugs.com, Temazepam food interactions — Consumer interaction checker; alcohol and obesity/pharmacokinetic notes only, no nutrient interaction listed
  5. RxList, Restoril drug information — Consumer drug page; no vitamin, mineral, or supplement interaction listed for temazepam
  6. PubMed search: "temazepam AND oxidative stress" — Zero results
  7. PubMed search: "temazepam AND mitochondria" — Zero results
  8. PubMed search: "temazepam AND microbiome" — Zero results
  9. PubMed search: "benzodiazepine translocator protein mitochondria temazepam" — Zero results
  10. PubMed search: "temazepam AND copper" — Zero results in the original review; re-run in this repair pass with the same zero-result outcome
  11. PubMed search: "temazepam AND ceruloplasmin" — Repair-pass addition, attempted as a second copper phrasingInaccessible: blocked this session by a persistent gateway-level policy denial (repeated 403 at the CONNECT level, confirmed via the proxy's own diagnostic), not simple rate limiting.
  12. PubMed search: "temazepam AND iron" — Two results, both excluded on the cohort/relevance testExcluded: Umbreit et al. 2021 (PMID 34032164) mentions temazepam only as one RLS treatment option among several, not a temazepam-iron study; Bekele et al. 2011 (PMID 21914556) is an unrelated water-quality paper.
  13. PubMed search: "temazepam AND ferritin" — Repair-pass addition; zero results, reinforcing the "temazepam AND iron" finding
  14. Sarnowska A, Beresewicz M, Zablocka B, et al. Diazepam neuroprotection in excitotoxic and oxidative stress involves a mitochondrial mechanism additional to the GABA-AR and hypothermic effects. Neurochem Int. 2009. PMID 19428822. — Tier B, drug-specific for diazepam, rat neuron cultureCohort note: diazepam, not temazepam. Cited as class extrapolation only.
  15. Ghasempouri SK, Askari Z, Mohammadi H. Ameliorative effect of diazepam against ethanol-induced mitochondrial disruption in brains of the mice. Toxicol Rep. 2023. PMID 37955036. — Tier B, drug-specific for diazepam, mouse modelCohort note: diazepam, not temazepam. Cited as class extrapolation only.
  16. Barresi E, Robello M, Costa B, et al. An update into the medicinal chemistry of translocator protein (TSPO) ligands. Eur J Med Chem. 2021. PMID 33081988. — Tier C, medicinal-chemistry review, not an outcome study
  17. Musavi S, Kakkar P. Effect of diazepam treatment and its withdrawal on pro/antioxidative processes in rat brain. Mol Cell Biochem. 2003. PMID 12708744. — Tier B, drug-specific for diazepam, rat brain, treatment and withdrawal phasesCohort note: diazepam, not temazepam. Cited as class extrapolation only.
  18. Mendez-Cuesta LA, Marquez-Valadez B, Perez-De La Cruz V, et al. Diazepam blocks striatal lipid peroxidation and improves stereotyped activity in a rat model of acute stress. Basic Clin Pharmacol Toxicol. 2011. PMID 21645264. — Tier B, drug-specific for diazepam, rat modelCohort note: diazepam, not temazepam. Cited as class extrapolation only.
  19. PubMed search: "benzodiazepine AND oxidative stress" — Broad search; no hit specific to any clinically used benzodiazepine's own drug-nutrient profile
  20. PubMed search: "diazepam AND mitochondria AND oxidative stress" — Source of the four diazepam citations above
  21. PubMed search: "benzodiazepine withdrawal AND oxidative stress" — Source of the Musavi and Kakkar 2003 citation above
  22. Lin W, et al. Flunitrazepam induces neurotoxicity in zebrafish through microbiota-gut-brain axis. Sci Total Environ. 2023. PMID 37532048. — Tier B/C, drug-specific for flunitrazepam, zebrafish, environmental exposure paradigmCohort note: flunitrazepam, not temazepam. Cited as class extrapolation only.
  23. PubMed search: "benzodiazepine AND gut microbiota" — Source of the Lin et al. 2023 citation above
  24. PubMed search: "benzodiazepine AND ATP production AND mitochondrial respiration" — Four results; see Bettendorff 1995 and Burbenskaya 1998 below
  25. Bettendorff L, Goessens G, Sluse F, et al. Thiamine deficiency in cultured neuroblastoma cells: effect on mitochondrial function and peripheral benzodiazepine receptors. J Neurochem. 1995. PMID 7722487. — Tier B, reverse-direction study (nutrient affects benzodiazepine-receptor expression, not the drug affecting the nutrient)Not usable as depletion evidence; direction is reversed.
  26. Burbenskaya NM, Nartsissov YR, Tsofina LM, Komissarova IA. The uncoupling effect of some psychotropic drugs on oxidative phosphorylation in rat liver mitochondria. IUBMB Life (published as Biochem Mol Biol Int at the time). 1998;45(2):261-268. PMID 9678247. — Tier B, drug-specific for diazepam (as Relanium) and imipramine (as Melipramine), isolated rat liver mitochondria; cited as class extrapolation for ATP production, not for temazepamCohort note: diazepam and imipramine, not temazepam. Direct PubMed and Europe PMC access were both blocked in the original review; cohort and findings confirmed in this repair pass via an OpenAlex per-record lookup (https://api.openalex.org/works/pmid:9678247). Cited as class extrapolation only.
  27. OpenAlex per-record lookup for PMID 9678247 — Fallback channel used after direct PubMed and Europe PMC access failed; returned title, journal details, and a reconstructed abstract confirming diazepam and imipramine as the two drugs tested
  28. PubMed search: "temazepam AND melatonin" — Ten results, all comparative-effectiveness or performance trials, listed individually below
  29. Mendis R, Wong A, Frenkel S, et al. Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer. J Palliat Med. 2024. PMID 39304187. — Comparative-effectiveness trial, not a depletion study
  30. Stenveld F, Bosman S, van Munster BC, et al. Melatonin, Temazepam and Placebo in Hospitalised Older Patients with Sleeping Problems (MATCH): a study protocol. BMJ Open. 2019. PMID 31122969. — Comparative-effectiveness trial protocol, not a depletion study
  31. Gilbert SS, van den Heuvel CJ, Dawson D. Daytime melatonin and temazepam in young adult humans: equivalent effects on sleep latency and body temperatures. J Physiol. 1999. PMID 9882760. — Comparator study, confirmed via OpenAlex fallback in this repair pass: melatonin (5mg) vs. temazepam (20mg) vs. placebo, 20 young adults; both reduced core body temperature and sleep latency comparably, only melatonin showed cardiac effects; endogenous melatonin secretion under temazepam was not measuredDirect PubMed abstract fetch was blocked again in this repair pass by a bot-verification page; full abstract obtained instead via OpenAlex per-record lookup (https://api.openalex.org/works/pmid:9882760).
  32. Rogers NL, Kennaway DJ, Dawson D. Neurobehavioural performance effects of daytime melatonin and temazepam administration. J Sleep Res. 2003. PMID 12941059. — Comparator study, confirmed via OpenAlex fallback in this repair pass: melatonin (5mg) vs. temazepam (10mg) vs. placebo, 16 young adults, crossover design; melatonin produced smaller memory-performance deficits than temazepam; endogenous melatonin secretion under temazepam was not measuredDirect PubMed abstract fetch was blocked again in this repair pass; full abstract obtained instead via OpenAlex per-record lookup (https://api.openalex.org/works/pmid:12941059).
  33. PubMed search: "benzodiazepine AND melatonin secretion" — Repair-pass addition, attempted as a class-level check for endogenous melatonin suppressionInaccessible: blocked this session by the same gateway-level policy denial described above.
  34. PubMed search: "diazepam AND pineal AND melatonin" — Repair-pass addition, attempted as a further class-level checkInaccessible: blocked this session by the same gateway-level policy denial described above.
  35. PubMed search: "benzodiazepine AND fracture risk AND bone mineral density" — Used only to support the fall/fracture mechanism clarification, not as graded nutrient evidence
  36. Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH. Bone mineral density in subjects using central nervous system-active medications. Am J Med. 2005. PMID 16378792. — Relevant title; abstract could not be openedInaccessible: Europe PMC abstract lookup was rate-limited. Not cited for any specific finding, listed for future re-check only.
  37. PubMed search: "temazepam AND oxygen saturation" — Repair-pass search; blocked in the original review, successfully completed this pass after a cooldown wait. Thirteen results across two pages; the five most directly relevant are listed individually below
  38. Dubowitz G. Effect of temazepam on oxygen saturation and sleep quality at high altitude: randomised placebo controlled crossover trial. BMJ. 1998. PMID 9518909. — Tier A, drug-specific RCT, n=11, Mount Everest base camp (5300m); temazepam 10mg vs. placebo. Mean saturation not significantly different (74.65% vs. 75.70%, p=0.54); temazepam produced significantly fewer large (>4%) desaturation events than placebo (p=0.0036)
  39. Stege G, et al. Temazepam 10mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respir Med. 2010. PMID 19910177. — Tier A, drug-specific, severe normocapnic COPD patients; found no negative effect on breathing or gas exchangeDirect PubMed abstract fetch was rate-limited in this pass; title and finding confirmed via OpenAlex per-record lookup (https://api.openalex.org/works/pmid:19910177), full quantitative abstract not obtained.
  40. Biberdorf DJ, et al. Benzodiazepines in congestive heart failure: effects of temazepam on arousability and Cheyne-Stokes respiration. Sleep. 1993. PMID 8235237. — Tier A, drug-specific, double-blind crossover, n=7 CHF patients. Overnight oxygen saturation essentially unchanged (~95.1%, <2.2% of time below 90%) between temazepam and placebo. CSR as a percent of sleep time fell from 38.7% to 32.5% (not statistically significant); apnea/hypopnea index rose numerically from 10 to 15.6 events/hour, significance not stated in the abstract obtained. Temazepam reduced microarousals and improved daytime alertnessDirect PubMed abstract fetch returned only page metadata (bot-verification) in this pass; full abstract obtained instead via OpenAlex per-record lookup (https://api.openalex.org/works/pmid:8235237). The AHI increase is flagged in the Fails verification entry as a partially discordant data point rather than omitted.
  41. Tanner JB, et al. A randomized trial of temazepam versus acetazolamide in high altitude sleep disturbance. High Alt Med Biol. 2013. PMID 24028643. — Tier A, drug-specific RCT, high altitude; no significant difference in mean nocturnal oxygen saturation between temazepam and acetazolamide (84.1% vs. 84.4%, p=0.57); temazepam gave superior subjective sleep qualityDirect PubMed abstract fetch was rate-limited in this pass; full finding obtained instead via OpenAlex per-record lookup (https://api.openalex.org/works/pmid:24028643).
  42. Mason M, et al. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2015. PMID 26171909. — Tier A, systematic review, 14 trials/293 participants, includes a temazepam 15mg trial among the hypnotics studied. No evidence of a deleterious effect on apnoea-hypopnoea index or oxygen desaturation for the hypnotics/benzodiazepines studied; contrasts with the opioid remifentanil, which did show significant desaturation. Evidence base rated poor quality overall; caution urged in prescribing to OSA patients outside studied cohortsDirect PubMed abstract fetch returned only page metadata (bot-verification) in this pass; full abstract obtained instead via OpenAlex per-record lookup (https://api.openalex.org/works/pmid:26171909).
  43. PubMed search: "temazepam AND magnesium" — Blocked by rate-limiting in the original review; re-attempted in this repair pass and blocked againInaccessible: blocked this session by the same gateway-level policy denial described above; not swept for this revision. Out of scope for this repair pass's five mandated categories, disclosed here only for continuity with the original review.